Work

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies

Year: 2025

Type: article

Source: British Journal of Haematology

DOI: 10.1111/bjh.70225

Authors: Miles Thomas, Hannah Johnston, Emily Dworkin, Austin Wesevich, Gregory W. Roloff, Caner Saygin, Mariam T. Nawas, Michael W. Drazer, Adam S. DuVall, Satyajit Kosuri, Michael J. Thirman, Olatoyosi Odenike, Wendy Stock, Richard A. Larson, Rafael Madero‐Marroquin, Anand A. Patel

Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,190

Funders: Amgen, Pfizer, AstraZeneca, Gilead Sciences, Ariad Pharmaceuticals, Celgene, TG Therapeutics, Incyte, Syndax Pharmaceuticals, Argenx, Astellas Pharma, Servier, Swedish Orphan Biovitrum, Genentech, Pharmacyclics, National Cancer Institute, Daiichi Sankyo Europe

OpenAlex ID: W4415568213

FWCI: 1.308

Cites: 14

Cited by: 2

Related to: